Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis

被引:138
|
作者
Dai, Jinlu [1 ]
Escara-Wilke, June [1 ]
Keller, Jill M. [1 ,2 ]
Jung, Younghun [3 ]
Taichman, Russell [3 ]
Pienta, Kenneth J. [4 ]
Keller, Evan T. [1 ,2 ,5 ]
机构
[1] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Dent, Periodont & Oral Med, Ann Arbor, MI 48109 USA
[4] Johns Hopkins Univ, Brady Urol Inst, Dept Urol, Baltimore, MD USA
[5] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2019年 / 216卷 / 12期
基金
美国国家卫生研究院;
关键词
EXPRESSION; CELLS; PKM2; MICROENVIRONMENT; PATHWAY; SWITCH;
D O I
10.1084/jem.20190158
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Prostate cancer (PCa) metastasizes selectively to bone through unknown mechanisms. In the current study, we identified exosome-mediated transfer of pyruvate kinase M2 (PKM2) from PCa cells into bone marrow stromal cells (BMSCs) as a novel mechanism through which primary tumor-derived exosomes promote premetastatic niche formation. We found that PKM2 up-regulates BMSC CXCL12 production in a HIF-1 alpha-dependent fashion, which subsequently enhances PCa seeding and growth in the bone marrow. Furthermore, serum-derived exosomes from patients with either primary PCa or PCa metastasis, as opposed to healthy men, reveal that increased exosome PKM2 expression is associated with metastasis, suggesting clinical relevance of exosome PKM2 in PCa. Targeting the exosome-induced CXCL12 axis diminished exosome-mediated bone metastasis. In summary, primary PCa cells educate the bone marrow to create a premetastatic niche through primary PCa exosome-mediated transfer of PKM2 into BMSCs and subsequent up-regulation of CXCL12. This novel mechanism indicates the potential for exosome PKM2 as a biomarker and suggests therapeutic targets for PCa bone metastasis.
引用
收藏
页码:2883 / 2899
页数:17
相关论文
共 50 条
  • [21] Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
    Dimitrios Anastasiou
    Yimin Yu
    William J Israelsen
    Jian-Kang Jiang
    Matthew B Boxer
    Bum Soo Hong
    Wolfram Tempel
    Svetoslav Dimov
    Min Shen
    Abhishek Jha
    Hua Yang
    Katherine R Mattaini
    Christian M Metallo
    Brian P Fiske
    Kevin D Courtney
    Scott Malstrom
    Tahsin M Khan
    Charles Kung
    Amanda P Skoumbourdis
    Henrike Veith
    Noel Southall
    Martin J Walsh
    Kyle R Brimacombe
    William Leister
    Sophia Y Lunt
    Zachary R Johnson
    Katharine E Yen
    Kaiko Kunii
    Shawn M Davidson
    Heather R Christofk
    Christopher P Austin
    James Inglese
    Marian H Harris
    John M Asara
    Gregory Stephanopoulos
    Francesco G Salituro
    Shengfang Jin
    Lenny Dang
    Douglas S Auld
    Hee-Won Park
    Lewis C Cantley
    Craig J Thomas
    Matthew G Vander Heiden
    Nature Chemical Biology, 2012, 8 : 839 - 847
  • [22] Pyruvate kinase M2: A multifarious enzyme in non-canonical localization to promote cancer progression
    Amin, Sajid
    Yang, Peng
    Li, Zhuoyu
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 331 - 341
  • [23] Protease-Activated Receptor-1 is Upregulated in Reactive Stroma of Primary Prostate Cancer and Bone Metastasis
    Zhang, Xiaotun
    Wang, Wenbin
    True, Lawrence D.
    Vessella, Robert L.
    Takayama, Thomas K.
    PROSTATE, 2009, 69 (07): : 727 - 736
  • [24] Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics
    Zhu, Susi
    Guo, Yeye
    Zhang, Xu
    Liu, Hong
    Yin, Mingzhu
    Chen, Xiang
    Peng, Cong
    CANCER LETTERS, 2021, 503 : 240 - 248
  • [25] Erratum: Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
    Dimitrios Anastasiou
    Yimin Yu
    William J Israelsen
    Jian-kang Jiang
    Matthew B Boxer
    Bum Soo Hong
    Wolfram Tempel
    Svetoslav Dimov
    Min Shen
    Abhishek Jha
    Hua Yang
    Katherine R Mattaini
    Christian M Metallo
    Brian P Fiske
    Kevin D Courtney
    Scott Malstrom
    Tahsin M Khan
    Charles Kung
    Amanda P Skoumbourdis
    Henrike Veith
    Noel Southall
    Martin J Walsh
    Kyle R Brimacombe
    William Leister
    Sophia Y Lunt
    Zachary R Johnson
    Katharine E Yen
    Kaiko Kunii
    Shawn M Davidson
    Heather R Christofk
    Christopher P Austin
    James Inglese
    Marian H Harris
    John M Asara
    Gregory Stephanopoulos
    Francesco G Salituro
    Shengfang Jin
    Lenny Dang
    Douglas S Auld
    Hee-Won Park
    Lewis C Cantley
    Craig J Thomas
    Matthew G Vander Heiden
    Nature Chemical Biology, 2012, 8 : 1008 - 1008
  • [26] Role of Pyruvate kinase M2 deficiency in cancer stemness property
    Sun, Kuang-Hui
    Sun, Wan-Hsuan
    Fang, Hsueh-Jou
    Peng, Ta-Jung
    CANCER SCIENCE, 2025, 116 : 464 - 464
  • [27] TUMOR PYRUVATE KINASE M2 AS BIOMARKER OF ESOPHAGEAL CANCER AND GERD
    Gupta, T.
    Chahal, K. S.
    INFLAMMATION RESEARCH, 2011, 60 : 46 - 46
  • [28] Synthesis of a Sulfonamide Pyruvate Kinase M2 Activator for Cancer Therapy
    Zhang, Qun-Zheng
    Zhang, Dian
    Huang, Fei
    Ke, Cong-Yu
    Pan, Qing
    Zhang, Xun-Li
    CURRENT ORGANIC SYNTHESIS, 2017, 14 (04) : 578 - 581
  • [29] Posttranslational Modifications of Pyruvate Kinase M2: Tweaks that Benefit Cancer
    Prakasam, Gopinath
    Iqbal, Mohammad Askandar
    Bamezai, Rameshwar N. K.
    Mazurek, Sybille
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [30] The Multifarious Functions of Pyruvate Kinase M2 in Oral Cancer Cells
    Kurihara-Shimomura, Miyako
    Sasahira, Tomonori
    Nakashima, Chie
    Kuniyasu, Hiroki
    Shimomura, Hiroyuki
    Kirita, Tadaaki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)